S
Steven E. Lipshultz
Researcher at University at Buffalo
Publications - 514
Citations - 65630
Steven E. Lipshultz is an academic researcher from University at Buffalo. The author has contributed to research in topics: Cardiomyopathy & Cardiotoxicity. The author has an hindex of 102, co-authored 505 publications receiving 57200 citations. Previous affiliations of Steven E. Lipshultz include Roswell Park Cancer Institute & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Ethnic group differences in cardiometabolic disease risk factors independent of body mass index among american youth
Sarah E. Messiah,Kristopher L. Arheart,Gabriela Lopez-Mitnik,Steven E. Lipshultz,Tracie L. Miller +4 more
TL;DR: The purpose of this analysis was to identify any ethnic group differences in the prevalence of cardiometabolic disease risk factors independent of BMI in United States youth.
Journal ArticleDOI
Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients.
TL;DR: Routine echocardiography is recommended for HIV-infected patients, even those with no evidence of cardiovascular disease, and preventive and therapeutic cardiovascular interventions are reviewed.
Journal ArticleDOI
Sex-related Differences in Mast Cell Activity and Doxorubicin Toxicity: A Study in Spontaneously Hypertensive Rats
Jun Zhang,Alan Knapton,Steven E. Lipshultz,Thomas R. Cochran,Hajime Hiraragi,Eugene H. Herman +5 more
TL;DR: The presence of sex-related differences in the cardiotoxic effects elicited by doxorubicin is demonstrated and variations in the level of cardiac MC activity are identified as a factor which could possibly contribute to the male-female dissimilarity.
Journal ArticleDOI
Pathogenesis of HIV-Associated Cardiomyopathy
TL;DR: A review article discusses HIV‐associated cardiovascular complications, focusing on pathogenetic mechanisms that may play a role in diagnosis, management, and therapy of these complications.
Journal ArticleDOI
Cardiomyopathy Caused by Antineoplastic Therapies.
Valeriano C. Simbre,M. Jacob Adams,Sampada S. Deshpande,Sarah A. Duffy,Tracie L. Miller,Steven E. Lipshultz +5 more
TL;DR: There is no specific treatment for cancer therapy-related cardiomyopathy, and symptomatic patients should receive standard treatments for congestive heart failure such as afterload reduction, beta-blockers, diuresis, and digoxin.